Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Alnylam Pharmaceuticals Inc. (ALNY)

117.66   5.17 (4.6%) 02-28 16:00
Open: 106.28 Pre. Close: 112.49
High: 118.54 Low: 106.28
Volume: 1,106,989 Market Cap: 13247M
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 118.816 - 119.603 119.603 - 120.315
Low: 104.487 - 105.412 105.412 - 106.248
Close: 116.107 - 117.691 117.691 - 119.123

Technical analysis

as of: 2020-02-28 4:26:11 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 144.51     One year: 157.11
Support: Support1: 106.28    Support2: 88.42
Resistance: Resistance1: 123.73    Resistance2: 134.51
Pivot: 126.06
Moving Average: MA(5): 117.96     MA(20): 124.19
MA(100): 109.02     MA(250): 91.10
MACD: MACD(12,26): -0.07     Signal(9): 1.81
Stochastic oscillator: %K(14,3): 20.53     %D(3): 19.32
RSI: RSI(14): 44.33
52-week: High: 134.51  Low: 65.81  Change(%): 38.4
Average Vol(K): 3-Month: 68138  10-Days: 64574

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
ALNY has closed above bottom band by 16.7%. Bollinger Bands are 58.9% wider than normal. The large width of the bands suggest high volatility as compared to ALNY's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue.

Headline News

Alnylam Announces Changes to its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the appointment of Dr. Olivier Brandicourt to its Board of Directors effective March 2, 2020. Dr. Brandicourt served as Chief Executive Officer and a member of the Board of Directors of Sanofi from 2015 to 2019. Prior to that he was CEO and chair of Bayer HealthCare from 2013 to 2015, and spent 13 years at Pfizer, including as a member of its Executive Leadership Tea

Alnylam Announces Approval in Brazil of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved ONPATTRO® (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy. hATTR amyloidosis is a rare, progressive condition that is considered endemic in Brazil, affecting more than 5,000 people.i Based on Nobel Prize-winni

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 112.20
Shares Float (M) 111.64
% Held by Insiders 0.83
% Held by Institutions 95.87
Shares Short (K) 4420
Shares Short P. Month (K)

Stock Financials

EPS -8.110
Book Value (p.s.) 12.820
PEG Ratio -0.40
Profit Margin
Operating Margin -427.50
Return on Assets (ttm) -29.6
Return on Equity (ttm) -64.7
Qtrly Rev. Growth 240.8
Gross Profit (p.s.) 1.735
Sales Per Share
EBITDA (p.s.) -8.220
Qtrly Earnings Growth
Operating Cash Flow (M) -278.43
Levered Free Cash Flow (M) -415.84

Stock Valuations

P/E -14.51
P/E Growth Ratio 0.05
P/BV 9.18
P/S 58.53
P/CF -47.41

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.